Service Line:+1-315-239-3085
Address:FL-4, Building A5, International Enterprise Community, Tianjin, China
Email:[email protected]
Introduction to scFv Antibody Phage Display Platform
scFv, the most commonly used recombinant antibody, is approximately 25 kDa in size and consists of a heavy chain (VH) and a light chain (VL) connected by a short flexible peptide. With its small size and high specificity, scFv can be large-scale produced in prokaryotic expression systems and is widely used for the diagnosis and treatment of viral, bacterial, toxin, and tumor antigens. KMD Bioscience has established a solid platform for scFv preparation with a well-established laboratory system for generating scFv antibodies derived from naïve or immunized mouse and rabbit spleen cells, hybridoma cells, and human B lymphocytes. We meet the different needs of customers, provide high-quality scFv library construction and other efficient scientific research technology services, saving experimental costs and time for customers, and contributing wisdom and strength to scientific research.
|
|
The Procedure of scFv Antibody Phage Display Construction Service
Related Services of scFv Antibody Phage Display
We combine our mature recombinant antibody expression platform with hybridoma technology and complete antibody sequencing technology to generate highly specific scFv to meet our customers' needs. In addition, we provide further scFv antibody library screening, scFv antibody expression and purification, functional studies, and antibody optimization so that they can be used in the next step of research.
|
|
Recommended Special Services
KMD Bioscience can provide customers with antibody related services, and its technology platform provides customers with higher quality services.
![]() |
![]() |
![]() |
|
|
|
scFv Antibody Phage Display Related Technical Service Resources
We are willing to share with you the rich technology and resources used in scFv antibody phage display related technical services to solve your doubts. If you need to view more, please refer to our related articles.
|
|
|
|